Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/12208
Title: End-of-life costs of medical care for advanced stage cancer patients
Authors: Kovacevic, Aleksandra
Dragojević Simić, Viktorija
Rancic, Nemanja
Jurisevic, Milena
Gutzwiller, Florian S.
Matter-Walstra K.
Jakovljevic, Mihajlo
Issue Date: 2015
Abstract: © 2015, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Background/Aim. Cancer, one of the leading causes of mortality in the world, imposes a substantial economic bur-den on each society, including Serbia. The aim of this study was to evaluate the major cancer cost drivers in Serbia. Methods. A retrospective, in-depth, bottom-up analysis of two combined databases was performed in order to quantify relevant costs. End-of-life data were obtained from patients with cancer, who deceased within the first year of the estab-lished diagnose, including basic demographics, diagnosis, tumour histology, medical resource use and related costs, time and cause of death. All costs were allocated to one of the three categories of cancer health care services: primary care (included home care), hospital outpatient and hospital inpatient care. Results. Exactly 114 patients were analyzed, out of whom a high percent (48.25%) had distant metasta-ses at the moment of establishing the diagnosis. Malignant neoplasms of respiratory and intrathoracic organs were lead-ing causes of morbidity. The average costs per patient were significantly different according to the diagnosis, with the highest (13,114.10 EUR) and the lowest (4.00 EUR) ones observed in the breast cancer and melanoma, respectively. The greatest impact on total costs was observed concerning pharmaceuticals, with 42% of share (monoclonal antibodies amounted to 34% of all medicines and 14% of total costs), followed by oncology medical care (21%), radiation therapy and interventional radiology (11%), surgery (9%), imaging diagnostics (9%) and laboratory costs (8%). Conclusion. Cancer treatment incurs high costs, especially for end-of-life pharmaceutical expenses, ensued from medical personnel tendency to improve such patients’ quality of life in spite of nearing the end of life. Reimbursement policy on mono-clonal antibodies, in particular at end-stage disease, should rely on cost-effectiveness evidence as well as documented clinical efficiency.
URI: https://scidar.kg.ac.rs/handle/123456789/12208
Type: article
DOI: 10.2298/VSP1504334K
ISSN: 0042-8450
SCOPUS: 2-s2.0-84920288589
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

395

Downloads(s)

12

Files in This Item:
File Description SizeFormat 
0042-84501504334K.pdf826.88 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons